安罗替尼胶囊联合AP方案治疗晚期非小细胞肺癌的效果及对毒副反应发生情况、CTC、Her-2与P-Akt的影响  

Effect of anlotinib capsule combined with AP regimen in the treatment of advanced non-small cell lung cancer and its influences on the occurrence of toxic and side effects,CTC,Her-2 and P-Akt

作　　者：刘鑫[1] 陈艳妮 LIU Xin;CHEN Yanni(Ankang Central Hospital,Ankang 725000,China)

机构地区：[1]安康市中心医院,陕西安康725000

出　　处：《临床医学研究与实践》2023年第20期21-24,共4页Clinical Research and Practice

摘　　要：目的探讨安罗替尼胶囊联合AP方案治疗晚期非小细胞肺癌的效果及对毒副反应发生情况、循环肿瘤细胞(CTC)、人表皮生长因子受体2(Her-2)与磷酸化丝氨酸苏氨酸蛋白激酶(P-Akt)的影响。方法选取2018年1月至2021年1月我院收治的84例晚期非小细胞肺癌患者,以随机数字表法将其分为对照组(AP方案治疗)和观察组(AP方案联合安罗替尼胶囊治疗),各42例。比较两组的治疗效果。结果观察组的疾病控制率显著高于对照组(P<0.05)。两组的胃肠道反应、白细胞减少、骨髓抑制、肝功能损害及肾功能损害发生率无明显差异(P>0.05)。治疗后,观察组的CTC阳性率以及Her-2、P-Akt表达水平均低于对照组(P<0.05)。治疗后,观察组的红细胞免疫黏附促进因子(FEER)、协同肿瘤红细胞花环(ATER)均高于对照组(P<0.05)。结论安罗替尼胶囊联合AP方案治疗晚期非小细胞肺癌有助于提高治疗效果,降低CTC阳性率,下调Her-2、P-Akt表达,且不会增加毒副反应。Objective To investigate the effect of anlotinib capsule combined with AP regimen in the treatment of advanced non-small cell lung cancer and its influences on the occurrence of toxic and side effects,circulating tumor cell(CTC),human epidermal growth factor receptor 2(Her-2)and phosphorylated serine threonine protein kinase(P-Akt).Methods A total of 84 patients with advanced non-small cell lung cancer admitted in our hospital from January 2018 to January 2021 were selected and divided into control group(AP regimen treatment)and observation group(AP regimen combined with anlotinib capsule treatment)by random number table method,with 42 cases in each group.The therapeutic effects of the two groups were compared.Results The disease comtrol rate in the observation group was significantly higher than that in the control group(P<0.05).There were no significant differences in the incidences of gastrointestinal reaction,leukopenia,bone marrow suppression,liver function damage and renal function damage between the two groups(P>0.05).After treatment,the positive rate of CTC and the expression levels of Her-2 and P-Akt in the observation group were lower than those in the control group(P<0.05).After treatment,the erythrocyte immune adhesion promoter(FEER)and associated tumor erythrocyte rosette(ATER)in the observation group were higher than those in the control group(P<0.05).Conclusion Anlotinib capsule combined with AP regimen in the treatment of advanced non-small cell lung cancer is helpful to improve the therapeutic effect,reduce the positive rate of CTC,and down-regulate the expression of Her-2 and P-Akt,and it will not increase the toxic and side effects.

关 键 词：安罗替尼胶囊 AP方案 晚期非小细胞肺癌 毒副反应 

分 类 号：R734.2[医药卫生—肿瘤]